A serum-stable branched dimeric anti-VEGF peptide blocks tumor growth via anti-angiogenic activity
Experimental & Molecular Medicine
;
: 514-523, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-214628
ABSTRACT
Angiogenesis is critical and indispensable for tumor progression. Since VEGF is known to play a central role in angiogenesis, the disruption of VEGF-VEGF receptor system is a promising target for anti-cancer therapy. Previously, we reported that a hexapeptide (RRKRRR, RK6) blocked the growth and metastasis of tumor by inhibiting VEGF binding to its receptors. In addition, dRK6, the D-form derivative of RK6, retained its biological activity with improved serum stability. In the present study, we developed a serum-stable branched dimeric peptide (MAP2-dRK6) with enhanced anti-VEGF and anti-tumor activity. MAP2-dRK6 is more effective than dRK6 in many respects inhibition of VEGF binding to its receptors, VEGF- and tumor conditioned medium-induced proliferation and ERK signaling of endothelial cells, and VEGF-induced migration and tube formation of endothelial cells. Moreover, MAP2-dRK6 blocks in vivo growth of VEGF-secreting colorectal cancer cells by the suppression of angiogenesis and the subsequent induction of tumor cell apoptosis. Our observations suggest that MAP2-dRK6 can be a prospective therapeutic molecule or lead compound for the development of drugs for various VEGF-related angiogenic diseases.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Péptidos
/
Datos de Secuencia Molecular
/
Neoplasias Colorrectales
/
Movimiento Celular
/
Secuencia de Aminoácidos
/
Neovascularización Fisiológica
/
Inhibidores de la Angiogénesis
/
Células Endoteliales
/
Suero
/
Factor A de Crecimiento Endotelial Vascular
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Experimental & Molecular Medicine
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS